BR112022002632A2 - Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5 - Google Patents

Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5

Info

Publication number
BR112022002632A2
BR112022002632A2 BR112022002632A BR112022002632A BR112022002632A2 BR 112022002632 A2 BR112022002632 A2 BR 112022002632A2 BR 112022002632 A BR112022002632 A BR 112022002632A BR 112022002632 A BR112022002632 A BR 112022002632A BR 112022002632 A2 BR112022002632 A2 BR 112022002632A2
Authority
BR
Brazil
Prior art keywords
compound
agonist activity
receptor agonist
salt
crystal form
Prior art date
Application number
BR112022002632A
Other languages
English (en)
Inventor
S Johnson Courtney
Hideomi Kijima
Janelle Bevill Melanie
Naoko Imura
Shuhei Otani
D Parent Stephan
Takayuki Fujito
Lee Houston Travis
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BR112022002632A2 publication Critical patent/BR112022002632A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5. um objetivo da presente invenção consiste em fornecer um composto com um equilíbrio aprimorado de atividade de agonista de receptor s1p5 em relação ao receptor s1p1, e uma forma adequada para substâncias de fármaco de componentes farmacêuticos. é fornecido o composto i que tem alta atividade de agonista seletiva de receptor s1p5 no receptor s1p1. além disso, as formas de cristal de composto i, os sais de composto i e as formas de cristal de sais do mesmo revelados na presente invenção são fornecidos como substâncias de fármaco de componentes farmacêuticos.
BR112022002632A 2019-08-20 2020-08-19 Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5 BR112022002632A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962889091P 2019-08-20 2019-08-20
PCT/JP2020/031326 WO2021033729A1 (ja) 2019-08-20 2020-08-19 Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形

Publications (1)

Publication Number Publication Date
BR112022002632A2 true BR112022002632A2 (pt) 2022-05-03

Family

ID=74660224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002632A BR112022002632A2 (pt) 2019-08-20 2020-08-19 Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5

Country Status (13)

Country Link
US (1) US20220289675A1 (pt)
EP (1) EP4019496B1 (pt)
JP (1) JP7409383B2 (pt)
KR (1) KR20220050886A (pt)
CN (1) CN114302873A (pt)
AU (1) AU2020334489A1 (pt)
BR (1) BR112022002632A2 (pt)
CA (1) CA3150303A1 (pt)
ES (1) ES2983098T3 (pt)
IL (1) IL290432A (pt)
MX (1) MX2022001820A (pt)
WO (1) WO2021033729A1 (pt)
ZA (1) ZA202201784B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017036A2 (pt) * 2018-02-22 2020-12-15 Ono Pharmaceutical Co., Ltd. Compostos com atividade agonista do receptor s1p5
MX2023014197A (es) * 2021-06-16 2024-01-18 Celgene Corp Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas.
WO2024129948A1 (en) * 2022-12-16 2024-06-20 Celgene Corporation Heterocyclic compounds as modulators of s1p5

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222495A (en) * 1986-11-21 1991-04-26 Haessle Ab Benzimidazole derivatives and pharmaceutical compositions
GB8725118D0 (en) * 1987-10-27 1987-12-02 Ciba Geigy Ag Rifamycin derivatives
JP2005020882A (ja) 2003-06-25 2005-01-20 Matsushita Electric Works Ltd モータアクチュエータ装置
JP2006064757A (ja) 2004-08-24 2006-03-09 Systec Kyowa:Kk ディスプレイ固定用スタンド
MX2007006916A (es) * 2004-12-13 2007-08-06 Ono Pharmaceutical Co Derivado de acido aminocarboxilico y uso medicinal del mismo.
AU2007257881B2 (en) * 2006-06-12 2011-06-16 Secura Bio Inc. Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
JP6673218B2 (ja) * 2014-12-04 2020-03-25 小野薬品工業株式会社 ジヒドロナフタレン誘導体
BR112020017036A2 (pt) * 2018-02-22 2020-12-15 Ono Pharmaceutical Co., Ltd. Compostos com atividade agonista do receptor s1p5

Also Published As

Publication number Publication date
AU2020334489A1 (en) 2022-03-03
MX2022001820A (es) 2022-03-17
ES2983098T3 (es) 2024-10-22
EP4019496A4 (en) 2023-01-11
JPWO2021033729A1 (pt) 2021-02-25
CN114302873A (zh) 2022-04-08
CA3150303A1 (en) 2021-02-25
IL290432A (en) 2022-04-01
TW202114984A (zh) 2021-04-16
WO2021033729A1 (ja) 2021-02-25
KR20220050886A (ko) 2022-04-25
US20220289675A1 (en) 2022-09-15
JP7409383B2 (ja) 2024-01-09
EP4019496B1 (en) 2024-06-05
ZA202201784B (en) 2024-02-28
EP4019496A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
BR112022002632A2 (pt) Sal e forma de cristal de composto que tem atividade de agonista do receptor s1p5
BR112015020302A2 (pt) derivado de pirazol
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112017010893A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112021019256A2 (pt) Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados
BR112016023422A8 (pt) dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
CR11119A (es) Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingozina 1-fosfato (sip)
PE20171243A1 (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
BR112015028096A2 (pt) forma cristalina de um hidrato, processo para a preparação da forma cristalina, composição farmacêutica, forma cristalina, combinação farmacêutica, hidrato cristalino e cristais
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
BR112015007360A8 (pt) Composição farmacêutica, e, método para a preparação de uma droga de combinação
BR112017010595A2 (pt) análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
BR112014007753A2 (pt) composição farmacêutica granular